A prostaglandin is any member of a group of lipid compounds that are derived enzymatically from fatty acids and have important functions in the animal body. Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. They are mediators and have a variety of strong physiological effects, such as regulating the contraction and relaxation of[…]
Prostaglandins: What are they and how do they work?
Glossary, Prostaglandin Tags: prostaglandin Jul 13, 2011
Temsirolimus Combo Therapy Increases Cancer Remission
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunosuppressant Tags: acute myeloid leukemiaAnnual Meetingcancer treatmentchemotherapy Jun 21, 2011
Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]
Everolimus shoots two very different birds with one stone; cancer cells and coronary stents
Drug Research & Development API, Immunosuppressant Tags: 159351-69-6Everolimuskinase inhibitor Jun 08, 2011
In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant[…]
Toremifene in the prevention and treatment of prostate cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: breast cancerprostate cancer Jun 03, 2011
Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to[…]
Elacridar – A Unique Delivery System Fighting Chemotherapy Resistance
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: cancer treatmentchemotherapyDocetaxelimatinibIrinotecanPaclitaxel Jun 03, 2011
Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]
Adalimumab sustains clinical remission after 2 years of therapy in Crohn’s disease
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: AdalimumabHumira May 27, 2011
Studies with Adalimumab and a TNF-α blockade shows promising results for Adalimumab therapy for joint pain. Joint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis[…]
LGM Pharma responds to soaring Potassium Iodide demands in the US amidst fears of radiation contamination in Japan and West Coast
Anti-Fungal, Drug Research & Development API May 17, 2011
For several years now, LGM Pharma has been a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged a longstanding partnership with GlaxoSmithKline, Eli[…]
Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer
Monoclonal Antibodies / mAb Tags: 180288-69-1chemotherapyHER2-positiveHerceptinTrastuzumab May 16, 2011
A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]
Levocloperastine Fendizoate: The Better Antitussive Agent Over Codeine
Drug Research & Development API May 05, 2011
Many of the antitussive agents available in the market today act on the CNS, and cause the adverse events mostly associated with them such as sedation, vomiting, and nausea. One in particular, codeine, can lead to drug dependence. Because of this, pharmaceutical companies were prompted to develop a peripherally-acting antitussive agent that minimizes these central[…]
Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI May 02, 2011
Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year. The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]